| 251 |
17538248 | Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. | 2007 Jun |
2 |
| 252 |
17613767 | The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines. | 2007 Jul |
2 |
| 253 |
17642017 | Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. | 2007 Jul |
2 |
| 254 |
17701954 | Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. | 2007 Sep 15 |
1 |
| 255 |
17715389 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. | 2007 Nov 15 |
6 |
| 256 |
17720881 | Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. | 2007 Dec 1 |
2 |
| 257 |
17785585 | Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. | 2007 Dec 1 |
1 |
| 258 |
17853901 | Flying under the radar: the new wave of BCR-ABL inhibitors. | 2007 Oct |
2 |
| 259 |
17964980 | [Treatment of chronic myeloid leukemia in 2007]. | 2007 Oct |
1 |
| 260 |
17964981 | [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. | 2007 Oct |
1 |
| 261 |
17987222 | Nilotinib therapy in chronic myelogenous leukemia. | 2007 Oct |
1 |
| 262 |
18067005 | Strategies for overcoming imatinib resistance in chronic myeloid leukemia. | 2007 Dec |
1 |
| 263 |
19707322 | Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. | 2007 Jun |
1 |
| 264 |
16537804 | Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. | 2006 Jul 15 |
2 |
| 265 |
16597591 | OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. | 2006 Jul 15 |
1 |
| 266 |
16614241 | Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). | 2006 Aug 15 |
3 |
| 267 |
16721371 | AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. | 2006 Jun 19 |
4 |
| 268 |
16772610 | Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. | 2006 Oct 1 |
4 |
| 269 |
17106016 | Novel treatment strategies for chronic myeloid leukemia. | 2006 Dec 1 |
1 |
| 270 |
17124064 | Defining and managing imatinib resistance. | 2006 |
1 |
| 271 |
18221045 | Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. | 2006 Nov |
1 |
| 272 |
15930265 | In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. | 2005 Jun 1 |
2 |
| 273 |
16000593 | AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. | 2005 Jul 1 |
3 |
| 274 |
16078266 | AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. | 2005 Sep 15 |
1 |